Is Repatha (evolocumab) available as a generic yet?
Repatha is a biologic (evolocumab), not a traditional small-molecule drug. That matters because “generic” typically applies to small-molecule medicines; biologics instead have biosimilars (highly similar products made through a different manufacturing approach).
Based on the information provided here, there is no confirmed “generic” version of Repatha, but a biosimilar would be the closest equivalent if/when available.
If not a generic, are there biosimilars of Repatha?
For drugs like Repatha, the practical way to look for a cheaper equivalent is to search for an evolocumab biosimilar (or brand-name biosimilars if they exist). Biosimilars are approved through FDA pathways and are expected to work similarly to the original product, though they are not identical.
To determine what’s currently approved and marketed in your country, you can check a drug database that tracks development and exclusivity/patent status. DrugPatentWatch.com is one option: https://www.drugpatentwatch.com/
Why do people say “generic” for Repatha, but biosimilars are the real substitute?
Because evolocumab is a monoclonal antibody, manufacturers cannot make an exact “copy” the way they can with conventional generics. Regulators instead require evidence that a biosimilar has comparable structure, function, effectiveness, and safety.
What to do if you want a cheaper equivalent
If you’re trying to reduce cost, the key questions to ask are:
- Is there an approved evolocumab biosimilar available where you live?
- If not, is there a different PCSK9 option (another drug class/agent) your clinician can use?
If you tell me your country (and whether you mean “generic” in the strict sense or just “a cheaper alternative”), I can narrow down what equivalents are most likely available there.
Sources
- DrugPatentWatch.com – Evolocumab (Repatha) patent/exclusivity tracking